Search
N,N-dimethylarginine
go.drugbank.com/drugs/DB01686ExperimentalIt is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells which is closely related to L-arginine, a conditionally-essential amino acid.
3'-phospho-5'-adenylyl sulfate
go.drugbank.com/drugs/DB02902Experimental3'-phospho-5'-adenylyl sulfate is a key intermediate in the formation by living cells of sulfate esters of phenols, alcohols, steroids, sulfated polysaccharides, and simple esters, such as choline sulfate
Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10596ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10597ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10600ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Texas/50/2012 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10776ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Massachusetts/2/2012 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10777ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Switzerland/9715293/2013 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10778ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/California/7/2009(H1N1)-like antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10802ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB10998ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen